MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.86
-3.21
-12.31%
Closed 16:00 09/24 EDT
OPEN
26.00
PREV CLOSE
26.07
HIGH
26.19
LOW
22.85
VOLUME
144.91K
TURNOVER
--
52 WEEK HIGH
40.82
52 WEEK LOW
17.00
MARKET CAP
1.10B
P/E (TTM)
-13.6396
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
BRIEF-Nuvalent Announces Business And Program Highlights And Reports Q2 2021 Financial Results
reuters.com · 09/08 10:40
Nuvalent Net Loss Widens as Operating Expenses More Than Double in Q2
MT Newswires · 09/08 07:29
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23)
Benzinga · 08/24 12:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NUVL. Analyze the recent business situations of Nuvalent, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NUVL stock price target is 38.50 with a high estimate of 42.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 48.28M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chief Executive Officer/Director
James Porter
Chief Financial Officer/Primary Contact
Alex Balcom
Vice President - Operations
Ruth Adams
Vice President
Benjamin Lane
Senior Director
Joshua Horan
Director
Sapna Srivastava
No Data
About NUVL
Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS1 and ALK kinases, along with multiple discovery-stage research programs. The Company's pipeline includes NVL-520 and NVL-655. NVL-520, is a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors. NVL-655, is a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third-generation ALK inhibitors.

Webull offers kinds of Nuvalent Inc stock information, including NASDAQ:NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.